Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal HIV viral load threshold for guiding extended infant prophylaxis.

The Journal of infection·2026
Same author

Reforming competitive global public health funding: Bridging equity and practice gaps.

PLOS global public health·2026
Same author

Evolution of the Performance of the Malaria Control Program in Burkina Faso: Analysis from 2020 to 2024.

Journal of epidemiology and global health·2026
Same author

Johns Hopkins Center for Humanitarian Health-Lancet Commission on health, conflict, and forced displacement: health in a world of crises and impunity.

Lancet (London, England)·2026
Same author

Quantification and reduction of the health sector's environmental impact.

Bulletin of the World Health Organization·2026
Same author

Knowledge, attitudes, and practices of Tougan population towards dengue in Burkina Faso in 2024.

Journal of public health in Africa·2026

Related Experiment Video

Updated: May 17, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Oral Lamivudine for Extended HIV Postnatal Prophylaxis.

Philippe Van de Perre1, Nicolas Meda2, Souleymane Tassembedo3

  • 1UMR 1058 'Pathogenesis and Control of Chronic and Emerging Infections', INSERM-Université Montpellier, Inserm ADR Languedoc-Roussillon, 60 rue de Navacelles, 34394, Montpellier Cedex 5, France. philippe.vande-perre@umontpellier.fr.

Paediatric Drugs
|March 3, 2026
PubMed
Summary

Extended postnatal prophylaxis (ePNP) can help eliminate pediatric HIV. Single-drug regimens like lamivudine are effective and safer than multi-drug options for HIV-exposed infants.

More Related Videos

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
07:18

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Experiment Videos

Last Updated: May 17, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
07:18

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Area of Science:

  • Pediatric infectious diseases
  • HIV/AIDS research
  • Pharmacology and drug safety

Background:

  • Preventing mother-to-child transmission (PMTCT) of HIV has advanced, but pediatric HIV elimination remains a challenge.
  • Extended postnatal prophylaxis (ePNP) is a strategy involving antiretroviral prophylaxis for HIV-exposed infants after the initial PMTCT period.
  • Current international recommendations need urgent updates to include ePNP.

Purpose of the Study:

  • To evaluate the efficacy, safety, pharmacology, genetic barrier to resistance, and practicality of various extended postnatal prophylaxis (ePNP) regimens.
  • To identify optimal ePNP strategies for preventing pediatric HIV transmission.
  • To inform international guidelines for PMTCT.

Main Methods:

  • Review and analysis of studies on antiretroviral drugs used in ePNP, including lamivudine, nevirapine, lopinavir/ritonavir, and zidovudine.
  • Comparison of single-drug versus multi-drug ePNP regimens based on protective efficacy, toxicity, and other criteria.
  • Consideration of factors like maternal HIV viral load to guide ePNP indication.

Main Results:

  • Multi-drug ePNP regimens showed no superior protective efficacy compared to single-drug regimens.
  • Combined antiretroviral drug regimens were associated with increased toxicity.
  • Lamivudine and nevirapine emerged as preferred single-drug options for ePNP.

Conclusions:

  • Single-drug ePNP regimens, particularly lamivudine or nevirapine, are recommended for their favorable benefit/risk profile.
  • ePNP guided by maternal HIV viral load can optimize prophylaxis for high-risk infants.
  • Future research should explore long-acting antiretrovirals and broadly neutralizing antibodies for pediatric HIV prevention.